Results of a multicenter international trial indicate MRI perfusion-diffusion mismatch can add a crucial three extra hours for safe administration of tissue plasminogen activator to treat qualified acute stroke patients.
Results of a multicenter international trial indicate MRI perfusion-diffusion mismatch can add a crucial three extra hours for safe administration of tissue plasminogen activator to treat qualified acute stroke patients.
The phase II Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) involved 101 patients with acute ischemic stroke at 15 sites in Australia, New Zealand, Belgium, and Scotland. They all arrived in the emergency room more than three hours after symptom onset, which would usually disqualify them for clot-busing tPA treatment. Under these experimental conditions, however, 52 patients with DWI/PWI mismatch were randomly selected to receive tPA up to six hours after symptom onset. Another 49 with mismatch were given a placebo.
Investigators found that tPA can restore cerebral blood flow and improve clinical outcomes in these patients. "Although we did not find a statistically significant difference in functional outcome, there was a strong trend to improved outcome in the tPA group," said principal investigator Dr. Stephen M. Davis, a professor of neurology at the University of Melbourne in Australia.
He reported a 7.7% rate of symptomatic intracranial hemorrhage among patients who received tPA in the three to six-hour time frame and no instances of ICH for patients who received the placebo. The findings were consistent with rates reported in previous studies for sub-three hour tPA administration, he said.
"The results add weight to the idea that these are responders to tPA and possibly other reperfusion techniques beyond the current time window of three hours," Davis said. "Still, further studies should be done to confirm the clinical benefits beyond three hours."
Findings were announced at the American Stroke Association's 2008 International Conference in New Orleans.
-By H.A. Abella
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.